
    
      This is a randomized, double-blind, placebo-controlled, multicenter, global Phase III study
      to determine the efficacy and safety of transarterial chemoembolization (TACE) treatment in
      combination with durvalumab monotherapy or TACE given with durvalumab plus bevacizumab
      therapy compared to TACE therapy alone in patients with locoregional hepatocellular carcinoma
      not amenable to curative therapy
    
  